Eugene

[email protected]

LATEST

Takeda Receives US Clearance for Proposed $62-Billion Buy of Shire
By

By
Takeda Pharmaceutical Company has received unconditional clearance from the US Federal Trade Commission (FTC) for the company’s proposed $62-billion acquisition of Shire that was announced on May 8, 2018. In…

Recipharm Launches Stand-Alone Serialization Service
By

By
Recipharm, a Jordbro, Sweden-based contract development and manufacturing organization, has launched a stand-alone serialization service for meeting a compliance deadline of February 2019 for certain requirements of the European Union…

Amphstar To Expand Scope of Subsidiary for External Mfg
By

By
Amphastar Pharmaceuticals, a Rancho Cucamonga, California-based specialty pharmaceutical company, has announced plans to expand the scope of its subsidiary, Amphastar Nanjing Pharmaceuticals (ANP).   Amphastar is a specialty pharmaceutical company…

Fermion Completes Small-Molecule API Expansion
By

By
Fermion Oy, a Espoo, Finland-based, a manufacture of small-molecule active pharmaceutical ingredients (APIs), has commissioned a new manufacturing facility in Hanko, Finland, to replace an older manufacturing unit. Fermion Oy…

Novartis, Sandoz Recall 470,000 Prescription Drug Blister Packages
By

By
Novartis and Sandoz, its generics arm, have initiated a recall of 470,000 blister packages of 12 prescription drugs in the US because certain blister card packages distributed in the US…

US Senators Call on GSK to Address Shortage of Shingles Vaccine Shingrix
By

By
US Senators Amy Klobuchar (D-MN) and Tina Smith (D-MN) have sent a letter calling on Emma Walmsley, Chief Executive Officer, GlaxoSmithKline (GSK), to take action to alleviate a shortage of…

Lundbeck Names New President and CEO
By

By
Deborah Dunsire, MD, has been named as the new President and Chief Executive Officer (CEO) of H. Lundbeck A/S, a Valby, Denmark-based pharmaceutical company, effective September 1, 2018. She will…

Evonik To Expand CDMO Facilities for Injectables
By

By
Evonik has announced plans to invest EUR 35 million ($41 million) to expand its contract development and manufacturing (CDMO) capabilities in North America for controlled-release injectable formulations. The expansion of…

WuXi Biologics, Immune Pharmaceuticals in mAb Development and Mfg Pact
By

By
WuXi Biologics, part of WuXi AppTec, a Shanghai, China-headquartered contract service provider, has formed a development and manufacturing pact with Immune Pharmaceuticals, a New York-headquartered clinical-stage biopharmaceutical company focused on…

Rubius To Build $155-Million Cell Therapy Mfg Facility
By

By
Rubius Therapeutics, a Cambridge, Massachusetts-headquartered biopharmaceutical company developing cellular therapies, is investing up to $155 million to establish a manufacturing facility in Rhode Island. Rubius intends to invest up to…